Phase II evaluation of mitomycin C (MMC) in children with refractory solid tumors using the single high-intermittent-dose schedule
- 1 January 1981
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 9 (4) , 405-407
- https://doi.org/10.1002/mpo.2950090414
Abstract
Nine evaluable patients with refractory solid tumors received mitomycin C as a single intravenous injection at a dose of 20 mg/m2 at 6‐ to 8‐week intervals. Toxicity was tolerable. One patient with Wilms'tumor had a transient decrease in liver size. Pharmacokinetic data on three patients have suggested that the disposition of mitomycin C were comparable to those obtained in adults.Keywords
This publication has 3 references indexed in Scilit:
- Mitomycin C in large infrequent doses in breast cancerMedical and Pediatric Oncology, 1976
- Phase II study of porfiromycin vs mitomycin‐c utilizing acute intermittent schedulesMedical and Pediatric Oncology, 1976
- Clinical experience with mitomycin C in large infrequent dosesCancer, 1972